Tripeptide-1 (GHK Basic) Actions on Skin Cells and Underlying Connective Tissues

Tripeptide-1 is hypothesized to be a short-chain peptide composed of the amino acids glycine, histidine, and lysine, arranged in the sequence GHK. Scientists pioneering research on Tripeptide-1, such as Pickart et al., suggest that this peptide motif appears to replicate an endogenous fragment that is reportedly produced by several types of cells, including fibroblasts, lymphocytes, and macrophages.⁽¹⁾ It has also been proposed by Maquart et al. that the same sequence may exist within the structure of type I collagen, a fibrillar collagen subtype considered the most prevalent structural protein in connective tissues.⁽²⁾

The tripeptide may be generated as a result of the enzymatic breakdown of mature collagen fibers, potentially acting as a bioactive fragment that signals surrounding cells to initiate new collagen synthesis. Additionally, Tripeptide-1 has been suggested to exhibit a high affinity for copper ions (Cu²⁺), suggesting the ability to form a stable copper-peptide complex.

This complex may interact with enzymes that depend on metal cofactors—particularly matrix metalloproteinases (MMPs) and superoxide dismutase—thereby possibly modulating redox activity and supporting cellular responses related to oxidative stress, inflammation, or tissue regeneration. Consequently, it has been hypothesized that Tripeptide-1 may promote collagen production, exert antioxidant-like actions, and attenuate pro-inflammatory signaling in controlled laboratory settings.

 

Research

Tripeptide-1 and Collagen Synthesis

As previously mentioned, Maquart et al. suggest that there is a “presence of a Tripeptide-1 triplet in the alpha 2(I) chain of type I collagen”, specifically in residues 853‑855.⁽²⁾ Researchers have posited that, upon collagen degradation by proteases, fragments containing the Gly-His-Lys (GHK) motif are seemingly liberated into the extracellular milieu. These fragments resemble endogenous collagen breakdown products and may act as molecular cues, potentially instructing resident fibroblasts to reestablish collagen homeostasis by increasing the synthesis of new collagen.

Mechanistically, the researchers suggest that by simultaneously mimicking a collagen breakdown fragment and binding endogenous copper with high affinity, Tripeptide-1 may then facilitate copper uptake into fibroblasts. Increased intracellular copper availability, possibly tied to lysyl oxidase activity or other copper-dependent enzymes, might then support collagen post-translational processing or secretion, thereby leading to elevated extracellular collagen deposition.

The experiment by Maquart et al. also suggests that the peptide does not increase substrate availability, and instead may work solely as regulating the activity of prolyl or lysyl hydroxylases, which are copper-dependent enzymes in fibroblasts. Therefore, these events potentially culminate in more efficient collagen synthesis and secretion, thereby contributing to tissue repair. However, further research by Canapp et al. suggests that Tripeptide-1 may also support the breakdown of collagen and other extracellular matrix components by supporting the activity of MMPs.⁽³⁾ The researchers experimented on research models displaying signs of injury, which expressed elevated markers of pro-MMP-2 and pro-MMP-9 synthesis.

Tripeptide-1 exposure in these research models was associated with lower concentrations of both pro- and active MMP-2 and MMP-9. Although MMPs are essential for normal cell migration and the removal of denatured matrix, overly high MMP levels may strip newly synthesized collagen. By mitigating the abundance of active MMPs, Tripeptide-1 may mitigate collagen turnover at a rate that allows for more orderly collagen deposition and maturation. Tripeptide-1 is believed to achieve this in part by taking up copper ions, which are involved in MMP activation.

In the absence of excessive MMP activity, collagen and provisional matrix proteins (such as fibronectin and laminin) are less likely to be prematurely degraded. This creates an environment in which fibroblasts and myofibroblasts might deposit fibrillar collagens, providing tensile strength and supporting microvascular ingrowth.

Tripeptide-1 and Connective Tissue

Thanks to its potential to upregulate collagen synthesis and mitigate collagen breakdown by downregulating MMP, Tripeptide-1 may create a more stable collagen scaffold. This may ultimately support cellular proliferation and overall connective tissue recovery observed in research models. This potential appears to be prominent in wounded research models exposed to serum components such as fibrin, fibronectin, and latent growth factors.

Tripeptide-1 may coordinate with Cu²⁺ in these proteins, potentially facilitating catalytic actions that remodel the extracellular matrix and possibly promoting angiogenesis. Research by Mulder et al. suggests that when Tripeptide-1 is exposed to wounded research models immediately after debridement, the peptide may lead to approximately 98 % tissue recovery compared to around 61 % in unexposed controls.⁽⁴⁾

Additionally, research models exposed to Tripeptide-1 appear less likely to exhibit bacterial growth, with an approximately 7% colonization rate versus 34% in controls. The peptide may achieve that by hastening wound recovery or by modulating the recruitment and activation of immune cells during wound recovery processes observed in laboratory settings.

Tripeptide-1–Mediated Protection of Skin Cells from UVB

Under ultraviolet B (UVB) irradiation, skin cells may experience an increase in reactive oxygen species (ROS) and reactive carbonyl species (RCS). UVB exposure may also deplete glutathione (GSH), potentially impairing the detoxification of both ROS and RCS. As a result, RCS may accumulate intracellularly and form adducts with essential proteins, leading to cytotoxic implications in the form of morphological changes, loss of monolayer integrity, and necrotic regions in culture, as observed in research models.

Laboratory data from Cebrián et al. suggest that Tripeptide-1 may potentially protect skin cells against UVB by scavenging RCS. This is believed to preserve endogenous antioxidant defenses.⁽⁵⁾ By quenching RCS, Tripeptide-1 might spare GSH from excessive utilization. In murine keratinocyte cultures pre-exposed to Tripeptide-1 before UVB exposure, extracellular levels of GSH–RCS conjugates were mitigated compared to UVB-only controls, implying that Tripeptide-1 assumes part of the detoxification burden. This sparing of GSH may help cells maintain redox balance when facing subsequent ROS challenges, potentially preserving mitochondrial function and overall viability.

Morphologically, keratinocytes exposed to Tripeptide-1 and UVB may retain their normal architecture, whereas control cells often develop vacuolization, membrane blebbing, and eventual detachment. UVB irradiation may also induce reactive nitrogen species (RNS). Although Tripeptide-1 is not characterized as an RNS scavenger, it may indirectly mitigate RNS formation or downstream nitrative modifications by maintaining cellular redox status through GSH preservation and RCS quenching.

For example, UVB may elevate nitric oxide synthase activity in keratinocytes, generating nitric oxide that reacts with superoxide to form peroxynitrite. By preserving superoxide dismutase (SOD) function—possibly through a partially mitigated oxidative burden—Tripeptide-1 may indirectly reduce peroxynitrite accumulation and subsequent protein tyrosine nitration. When Tripeptide-1 is evaluated in glycation assays where SOD is the model protein in question, SOD activity appears preserved.

This preservation may occur because Tripeptide-1 competes with SOD for reactive carbonyl intermediates such as glyoxal and methylglyoxal. By reacting more rapidly with these aldehydes, Tripeptide-1 may mitigate crosslinking and modification of SOD, suggesting that it may similarly mitigate glycation of intracellular proteins in keratinocytes. The maintenance of SOD activity under oxidative conditions may further support defenses against superoxide radicals, which tend to accumulate during exposure to UVB radiation.

Overall, the researchers concluded that Tripeptide-1 “is][ able to help the [endogenous] protection of cells (GSH) to mitigate the damage of RCS and UVB radiation and acts as a scavenger of specific RCS (HNE, acrolein) and mitigates glycation of protein, avoiding the formation of advanced glycation end-products.”⁽⁵⁾

You can find GHK Basic for sale with 99% purity, on our website (available for research use only).

NOTE: These products are intended for laboratory research use only. This peptide is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.

 

References:

1. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. doi: 10.1155/2015/648108. Epub 2015 Jul 7. PMID: 26236730; PMCID: PMC4508379.
2. Maquart, F. X., Pickart, L., Laurent, M., Gillery, P., Monboisse, J. C., & Borel, J. P. (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS letters, 238(2), 343–346. https://doi.org/10.1016/0014-5793(88)80509-x
3. Canapp, S. O., Jr, Farese, J. P., Schultz, G. S., Gowda, S., Ishak, A. M., Swaim, S. F., Vangilder, J., Lee-Ambrose, L., & Martin, F. G. (2003). The effect of topical tripeptide-copper complex on the healing of ischemic open wounds. Veterinary surgery: VS, 32(6), 515–523. https://doi.org/10.1111/j.1532-950x.2003.00515.x
4. Mulder, G. D., Patt, L. M., Sanders, L., Rosenstock, J., Altman, M. I., Hanley, M. E., & Duncan, G. W. (1994). Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound repair and regeneration: official publication of the Wound Healing Society [and] the European Tissue Repair Society, 2(4), 259–269. https://doi.org/10.1046/j.1524-475X.1994.20406.x
5. Cebrián, J., Messeguer, A., Facino, R. M., & García Antón, J. M. (2005). New anti-RNS and -RCS products for cosmetic treatment. International journal of cosmetic science, 27(5), 271–278. https://doi.org/10.1111/j.1467-2494.2005.00279.x